The central claim of the review is that reactive oxygen species, long recognized as master regulators of cell fate, can kill a cell by disabling a specific lipid kinase that maintains endosomal identity. That kinase is the class III phosphatidylinositol 3-kinase, better known in the field as PIK3C3 or VPS34. VPS34 is responsible for generating phosphatidylinositol 3-phosphate, or PI3P, a signaling lipid that decorates early endosomes and recruits the effector proteins needed for vesicular trafficking, endosomal maturation, and autophagy initiation. According to the authors, when oxidative stress reaches a critical level, ROS oxidize and inactivate VPS34. The resulting depletion of PI3P strips endosomes of their molecular identity, disrupts the trafficking networks that depend on it, and sets in motion a cascade that ends with the accumulation of enlarged, dysfunctional vacuoles and progressive cellular collapse.

What makes triaptosis mechanistically distinctive is its stubborn persistence in the face of interventions that block every canonical death pathway. The review emphasizes that triaptosis proceeds even when caspases are inhibited, when necroptotic signaling is suppressed, and when lipid peroxidation is prevented. In other words, a cell undergoing triaptosis does not die because its executioner caspases have been activated, because its membrane lipids have been oxidized in the manner characteristic of ferroptosis, or because inflammatory necroptotic machinery has fired. Instead, the defining lesion is the ROS-driven failure of endosomal homeostasis. This pharmacological independence is precisely what elevates triaptosis from a curiosity to a candidate for a genuinely separate cell death program, and it offers researchers a new set of experimental handles for distinguishing it from apoptosis, ferroptosis, necroptosis, and pyroptosis in cultured cells and tissues.

The spatial logic of the pathway is central to the authors’ argument. Redox signaling, they stress, is not a uniform flood of oxidizing molecules but a spatially organized and context-dependent system in which specific organelles experience specific oxidative insults. Established ROS-regulated death pathways have largely been interpreted through mitochondrial dysfunction, lipid peroxidation, inflammatory signaling, and DNA damage, leaving the endosomal system underexplored as a primary target of oxidative killing. Triaptosis fills that gap by proposing that the endosome itself can be the decisive target. In this view, ROS-mediated cytotoxicity may arise through targeted organelle failure alongside mitochondrial dysfunction, lipid peroxidation, and nuclear damage, expanding the conceptual map of how oxidants decide whether a cell survives, adapts, or dies.

A key question for any proposed death pathway is what determines whether a given cell succumbs. For triaptosis, the review identifies the answer in the cell’s redox buffering capacity, the biochemical machinery that keeps reactive oxygen species in check. Two components loom largest. The first is glutathione, the abundant intracellular antioxidant that directly neutralizes oxidants and maintains protein thiols in their reduced state. The second is the KEAP1-NRF2 pathway, the master transcriptional circuit that senses electrophilic and oxidative stress and, in response, upregulates a broad program of antioxidant and detoxifying genes. Together, glutathione levels and KEAP1-NRF2 activity set the threshold at which VPS34 becomes oxidized and PI3P begins to disappear. Cells with robust buffering can tolerate oxidative insults that would push a poorly buffered neighbor over the edge into endosomal collapse.

This threshold concept has immediate implications for how scientists might study and manipulate the pathway. Because triaptosis depends on VPS34 oxidation rather than on any single downstream executioner, the susceptibility of a cell is essentially a function of how close its redox state sits to the point of kinase failure. Experimental manipulations that deplete glutathione, inhibit NRF2 signaling, or otherwise erode antioxidant defenses would be expected to lower the threshold, allowing oxidative stresses that are otherwise survivable to trigger PI3P loss and vacuolar catastrophe. Conversely, reinforcing antioxidant capacity should raise the threshold and protect cells. This framework turns triaptosis into a quantifiable phenomenon: rather than asking simply whether ROS are present, researchers can ask whether a cell’s buffering capacity has been pushed below the level needed to keep VPS34 functional.

The therapeutic implications, particularly in oncology, form one of the most provocative threads of the review. Cancer cells frequently live in a state of elevated basal oxidative stress, a consequence of oncogenic signaling, metabolic reprogramming, and rapid proliferation. To survive, they compensate by shoring up their antioxidant systems, often relying heavily on glutathione metabolism and NRF2-driven transcription. The authors argue that this adaptation places many tumors in a near-threshold redox state, poised perilously close to the point at which VPS34 oxidation and PI3P depletion begin. In such cells, a modest additional oxidative push, or a targeted erosion of glutathione buffering, could selectively tip the balance toward endosomal collapse while sparing normal cells that operate with a wider redox margin. Triaptosis thus offers a conceptual route to exploiting a well-known vulnerability of cancer cells through an organelle-specific mechanism that has not previously been targeted.

The review also situates triaptosis within the broader network of ROS-regulated cell death, drawing careful distinctions between the new pathway and its established relatives. Apoptosis is executed by caspases and characterized by nuclear fragmentation and membrane blebbing; ferroptosis depends on iron-catalyzed lipid peroxidation of cellular membranes; necroptosis and pyroptosis are lytic, inflammatory programs driven by dedicated signaling complexes. Triaptosis shares none of these execution mechanisms and is instead defined by the loss of PI3P-dependent endosomal identity and the accumulation of dysfunctional vacuoles. The authors integrate the pathway into the ROS-RCD network as a parallel branch rather than a variant of any existing program, suggesting that the cellular response to oxidative stress may branch at an early point: if mitochondria, membranes, and DNA hold, the endosomal system may nonetheless fail, and that failure alone can be lethal.

As a review article, the work synthesizes and interprets rather than reports a single decisive experiment, and the authors are careful to frame triaptosis as an emerging framework whose boundaries remain to be mapped. Open questions include precisely how ROS oxidize VPS34 in living cells, which cysteine residues or cofactors are most vulnerable, how quickly PI3P must be depleted before endosomal identity is irreversibly lost, and whether the enlarged vacuoles that characterize the pathway are cause or consequence of the final collapse. It will also fall to future work to identify biomarkers that distinguish triaptosis in pathological tissue and to develop pharmacological tools that modulate the pathway selectively. The study was supported by a grant from New York University Abu Dhabi, and the authors declare no competing interests.

Even with those caveats, the appearance of triaptosis in the cell death literature marks a notable conceptual shift. It relocates a decisive node of oxidative cell death from the power plants and archives of the cell to its logistics network, and it reframes redox toxicity as a matter of targeted organelle failure rather than indiscriminate damage. If subsequent experimental work confirms and refines the mechanism, triaptosis could reshape how researchers think about oxidative stress in cancer therapy, neurodegeneration, and inflammatory disease, and it may inspire a search for other organelle-centered death programs hiding in plain sight. For a field that has spent decades cataloguing the ways cells die, the message is that the map is still expanding, and that some of the most important territory may lie in the smallest of cellular compartments.

Subject of Research: An endosome-centered mechanism of ROS-regulated cell death involving oxidative inactivation of VPS34 and depletion of PI3P

Article Title: Triaptosis: an emerging endosome-centered mechanism of ROS-regulated cell death

Article References: Thayyullathil, F., Cheratta, A. R., & Galadari, S. (2026). Triaptosis: an emerging endosome-centered mechanism of ROS-regulated cell death. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03368-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03368-5

Keywords: triaptosis, cell death, reactive oxygen species, endosomes, VPS34, PI3P, oxidative stress, glutathione, KEAP1-NRF2, ferroptosis, apoptosis, cancer therapy

The protein in question is PIK3C3, better known in the research world as VPS34. First identified decades ago in yeast cells as a traffic controller that sorts and shuttles proteins to and from the cell membrane, VPS34 later earned fame for a second role: autophagy, the recycling program by which cells break down their own components to survive stress. Because fast-growing tumors depend heavily on autophagy to weather nutrient shortages and to dispose of substances that might otherwise alert the immune system, VPS34 has long been an attractive target for cancer researchers. The new study, published in the journal Autophagy, reveals that its importance extends beyond keeping tumor cells alive — it also determines how easily those cells can be spotted by the body’s defenses.

The key molecule in this story is GD2, a fatty substance with a small sugar chain that decorates the surface of neuroblastoma cells. Anti-GD2 immunotherapy works through lab-made monoclonal antibodies, such as dinutuximab and naxitamab, which are engineered to latch onto GD2 and flag the tumor for destruction by the patient’s own immune cells. The Penn State team, led by corresponding author Hong-Gang Wang, Lois High Berstler Professor of Pediatrics, found that inhibiting VPS34 raised the amount of GD2 displayed on the tumor cell surface. More GD2 means more docking sites for the antibodies — in Wang’s words, the tumor cells become more visible and give the antibodies more to latch onto.

The experimental evidence came from a series of careful measurements. When the researchers blocked VPS34 in cell cultures, they used flow cytometry, a technique that tags specific molecules with fluorescent markers and passes individual cells through a laser to quantify them. The treated cells glowed brighter, indicating elevated surface GD2. Intriguingly, blocking VPS34 increased the total amount of GD2 inside the cells, but the surface pool rose disproportionately, shifting the balance toward the outer membrane where antibodies can reach it. The most exciting finding, Wang noted, was that VPS34 inhibition increased GD2 presentation, making the tumor more visible to the antibody.

Not every result followed the expected script. Because the team’s hypothesis was rooted in autophagy — the idea that starving tumor cells of their recycling machinery would weaken them — they anticipated that the effect would depend on nutrient stress. Yet when VPS34 was blocked in lab cultures, where oxygen and nutrients are plentiful and cells do not rely heavily on autophagy, the tumor cells died anyway, independent of any immunotherapy. This suggested that VPS34’s other, older function — endolysosomal trafficking, the routing of material to different cellular destinations including the membrane — was also at play.

To disentangle the two roles, the researchers ran control experiments targeting ATG14, a protein that partners with VPS34 specifically for autophagy while leaving VPS34’s trafficking duties untouched. Blocking ATG14 produced a dramatically reduced effect on GD2, pointing to endolysosomal trafficking as a central mechanism behind the increased surface display. In mouse models, meanwhile, tumors grew poorly when the team targeted ATG14 and other autophagy genes. The two functions of VPS34, Wang concluded, likely work in tandem to help neuroblastoma cells survive — which means disrupting them strikes the cancer from multiple directions at once.

The therapeutic payoff emerged when VPS34 inhibition was paired with monoclonal antibodies in both cells and mice. The combination outperformed either approach alone. According to first author Jiawen Zhang, a biomedical sciences doctoral student, the brighter cancer cells with elevated GD2 became easier targets not only for the antibodies but for the natural killer cells that bind to them. Once engaged, these NK cells release perforin, a protein that punches holes in the cancer cell membrane, and granzymes, enzymes that pass through those holes and trigger cell death. In both experimental systems, tumor growth was significantly suppressed, and in mice, survival improved. Combining the two therapies, Zhang said, gave better results.

The implications may reach beyond neuroblastoma. High levels of GD2 also appear on melanoma and osteosarcoma cells, but anti-GD2 immunotherapy is currently approved as standard care only for neuroblastoma. Wang suggested that the strategy could potentially be tested in other tumor types that express high GD2 on their surfaces, broadening the relevance of the work well past the pediatric population in which it was conceived. The concept — making tumors more conspicuous by manipulating their internal logistics — could in principle complement antibody-based therapies across several cancers.

Significant hurdles remain before patients benefit. VPS34 inhibitors are still largely confined to pre-clinical studies, and off-target effects frequently complicate experiments in living subjects. What is missing, Wang emphasized, is a clinical-grade VPS34 drug. He expressed hope that the findings will encourage the research community to view VPS34 as an important target and accelerate drug discovery and testing efforts to complement anti-GD2 immunotherapy. The study, he said, provides the pre-clinical evidence and rationale that, once better VPS34 inhibitors are developed, combining them with anti-GD2 antibodies could become an important neuroblastoma treatment strategy.

The research was carried out by a broad Penn State team that included Longgui Chen, research technologist; Todd D. Schell, professor of cell and biological systems; Giselle Saulnier Sholler, Four Diamonds Endowed Chair for Pediatric Oncology Research; Vladimir Spiegelman, THON Chair for Pediatric Cancer Research; and Yoshinori Takahashi, associate professor of pediatrics and of cell and biological systems. Xiaoming Liu, who conducted the research as a doctoral student and has since graduated, also contributed. Funding came from the National Institutes of Health’s National Cancer Institute through awards R01CA222349, R21CA252748 and R01CA304343, along with the Lois High Berstler Research Endowment and Four Diamonds. For families facing high-risk neuroblastoma, the work offers a concrete biological rationale for a combination approach that could turn an elusive cancer into an open target — and a reminder that sometimes the most powerful way to defeat a tumor is simply to make it impossible for the immune system to ignore.

Subject of Research: VPS34 inhibition as a strategy to enhance anti-GD2 immunotherapy in pediatric neuroblastoma

Article Title: Making pediatric cancer more ‘visible’ boosts immunotherapy response

Article References: Making pediatric cancer more ‘visible’ boosts immunotherapy response. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: neuroblastoma, pediatric cancer, immunotherapy, VPS34, GD2, monoclonal antibodies, autophagy, endolysosomal trafficking, natural killer cells, dinutuximab, naxitamab, preclinical study